Physician profile
Ada Wang
NPI 1952757973
$5,357.66
in general payments reported to CMS, 2019-2025
20 companies · $1,252 in 2025
The $1,252 reported for 2025 was more than what 85% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $2,179 · 2024: $1,926 · 2025: $1,252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,280 · Education: $78.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,279.66 |
| Education | $78.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $979.02 | 2023-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $668.39 | 2023-2025 | Caplyta |
| Alkermes, INC. | $652.93 | 2023-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $503.85 | 2023-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Abbvie INC. | $427.98 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $332.09 | 2023-2024 | Uzedy, Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $301.33 | 2023-2025 | Ingrezza |
| Indivior INC. | $297.84 | 2023-2024 | Perseris |
| Lundbeck LLC | $288.79 | 2023-2024 | Rexulti, Abilify Maintena |
| Axsome Therapeutics, INC. | $228.53 | 2023-2025 | Auvelity |
| Almatica Pharma LLC | $147.19 | 2023-2024 | Loreev Xr |
| Ironshore Pharmaceuticals INC. | $100.64 | 2023-2024 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $82.92 | 2023-2025 | Fanapt, Hetlioz |
| Corium, LLC | $65.58 | 2023-2024 | Azstarys |
| Merck Sharp & Dohme LLC | $58.43 | 2023 | Belsomra |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $57.72 | 2023-2024 | Quviviq |
| Tris Pharma INC | $54.48 | 2023-2024 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $49.53 | 2023-2024 | Trintellix |
| Biogen, INC. | $33.37 | 2024 | |
| Luye Pharma (USA) Ltd. | $27.05 | 2025 | Erzofri Extended-Release |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ada Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.